ABSTRACT
Synthesis of prodrugs of orally active COX-2 inhibitor 3 involving sulfamoyl (SO(2)NH(2)) and hydroxymethyl (CH(2)OH) groups, and their biological evaluation are described. Of these prodrugs, the N-propionyl sulfonamide sodium 3k was found to be much superior to the parent compound 3 and other marketed COX-2 inhibitors in carrageenan induced rat paw edema model of inflammation due to highly elevated drug levels in systemic circulation. This prodrug has a potential both for oral as well as parenteral administration due to impressive analgesic activity, antipyretic potency, and extraordinary water solubility.
Subject(s)
Benzothiazoles/administration & dosage , Cyclooxygenase 2 Inhibitors/administration & dosage , Enzyme Inhibitors/administration & dosage , Fever/drug therapy , Hyperalgesia/drug therapy , Prodrugs/administration & dosage , Sulfonamides/administration & dosage , Administration, Oral , Animals , Benzothiazoles/chemistry , Benzothiazoles/pharmacokinetics , Carrageenan/toxicity , Cyclooxygenase 1/chemistry , Cyclooxygenase 2/chemistry , Cyclooxygenase 2 Inhibitors/chemical synthesis , Cyclooxygenase 2 Inhibitors/pharmacology , Edema/chemically induced , Edema/drug therapy , Endotoxins/toxicity , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Fever/chemically induced , Foot , Humans , Hyperalgesia/chemically induced , Injections, Spinal , Male , Microsomes/enzymology , Molecular Structure , Prodrugs/chemical synthesis , Prodrugs/pharmacology , Rats , Rats, Wistar , Seminal Vesicles/enzymology , Solubility , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/pharmacologyABSTRACT
Synthesis and biological evaluation of possible prodrugs of COX-2 inhibitors involving sulfonamide and hydroxymethyl groups of 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamides are described. Out of many options, the sodium salt of N-propionyl sulfonamide demonstrated much improved pharmacological profiles and physicochemical properties suitable for oral as well as parenteral administration.
Subject(s)
Cyclooxygenase 2/drug effects , Cyclooxygenase Inhibitors/pharmacology , Prodrugs/pharmacology , Sulfonamides/pharmacology , Acylation , Animals , Area Under Curve , Biological Availability , Cyclooxygenase Inhibitors/chemistry , Cyclooxygenase Inhibitors/pharmacokinetics , Prodrugs/chemistry , Rats , Sulfonamides/chemistry , Sulfonamides/pharmacokineticsABSTRACT
Analogs of 1,5-diarylpyrazoles with a novel pharmacophore at N1 were designed, synthesized and evaluated for the in-vitro cyclooxygenase (COX-1/COX-2) inhibitory activity. The variations at/around position-4 of the C-5 phenyl ring in conjunction with a CF3 and CHF2 groups at C-3 exhibited a high degree of potency and selectivity index (SI) for COX-2 inhibition. The in-vivo evaluation of these potent compounds with a few earlier ones indicated the 4-OMe-phenyl analog and the 4-NHMe-phenyl analog with a CF3, and the 4-OEt-phenyl analog with a CHF2 group at C-3 to possess superior potency than celecoxib. In addition to its impressive anti-inflammatory, antipyretic, analgesic and anti-arthritic properties, compound (DRF-4367) was found to possess an excellent pharmacokinetic profile, gastrointestinal (GI) safety in the long-term arthritis study and COX-2 potency in human whole blood assay. Thus, compound was selected as an orally active anti-inflammatory candidate for pre-clinical evaluation.
Subject(s)
Cyclooxygenase Inhibitors/chemical synthesis , Cyclooxygenase Inhibitors/pharmacology , Prostaglandin-Endoperoxide Synthases/drug effects , Pyrazoles/chemical synthesis , Pyrazoles/pharmacology , Sulfonamides/chemical synthesis , Sulfonamides/pharmacology , Animals , Celecoxib , Cyclooxygenase 1 , Cyclooxygenase 2 , Cyclooxygenase 2 Inhibitors , Cyclooxygenase Inhibitors/pharmacokinetics , Drug Design , Drug Evaluation, Preclinical , Humans , Membrane Proteins , Models, Molecular , Molecular Structure , Pyrazoles/administration & dosage , Pyrazoles/pharmacokinetics , Rats , Rats, Wistar , Structure-Activity Relationship , Sulfonamides/administration & dosage , Sulfonamides/pharmacokinetics , Time FactorsABSTRACT
Andrographolide 1, the cytotoxic agent of the plant Andrographis paniculata was subjected to semi-synthetic studies leading to the preparation of a number of potent and novel analogues. Of the analogues synthesized, while 8,17-epoxy andrographolide 6 retained the cytotoxic activity of 1, ester derivatives of 6 exhibited considerable improvement in activity. Lower activity was observed when the epoxy moiety in the triacetate 9, derived from 6 was modified. Synthesis and structure-activity relationships are discussed.
Subject(s)
Antineoplastic Agents/pharmacology , Diterpenes/pharmacology , Andrographis , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemical synthesis , Cell Line, Tumor , Crystallography, X-Ray , Diterpenes/administration & dosage , Diterpenes/chemical synthesis , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Mice , Structure-Activity RelationshipABSTRACT
PAT5A [5-[4-[N-(2-pyridyl)-(2S)-pyrrolidine-2-methoxyl]phenylmethylene[thiazolidine-2,4-dione, malic acid salt]], a chemically distinct unsaturated thiazolidinedione, activates peroxisome proliferator-activated receptor gamma (PPARgamma) submaximally in vitro with the binding affinity approximately 10 times less than that of rosiglitazone, a highly potent thiazolidinedione. PAT5A reduces plasma glucose level and improves insulin sensitivity in insulin resistant db/db mice, similar to that of rosiglitazone, while exerting a relatively weak adipogenic effect. In contrast to rosiglitazone, PAT5A inhibits cholesterol and fatty acid biosynthesis suggesting that PAT5A possesses a unique receptor-independent non-PPAR related property. PAT5A induces qualitatively similar but quantitatively different protease digestion patterns and interacts with PPARgamma differently than rosiglitazone. PAT5A shows differential cofactor recruitment and gene activation than that of rosiglitazone. Thus, the partial agonism of PAT5A to PPARgamma together with its receptor independent effects may contribute to its antidiabetic potency similar to rosiglitazone in vivo despite reduced affinity for PPARgamma. These biological effects suggest that PAT5A is a PPARgamma modulator that activates some (insulin sensitization), but not all (adipogenesis), PPARgamma-signaling pathways.
Subject(s)
Adipocytes/drug effects , Hypoglycemic Agents/pharmacology , Pyridines/pharmacology , Receptors, Cytoplasmic and Nuclear/agonists , Thiazoles/pharmacology , Thiazolidinediones , Transcription Factors/agonists , 3T3 Cells , Adipocytes/metabolism , Animals , Binding Sites , Carrier Proteins/metabolism , Cyclic AMP Response Element-Binding Protein/metabolism , Histone Acetyltransferases , Mediator Complex Subunit 1 , Mice , Nuclear Receptor Coactivator 1 , Receptors, Cytoplasmic and Nuclear/metabolism , Rosiglitazone , Thiazolidines , Transcription Factors/metabolismABSTRACT
Pharmacokinetics of PAT-5A (a new thiazolidinedione derivative), a potent insulin sensitizing and lipid-lowering compound was studied in rats. A single dose of 3, 10, 30 and 100 mg/kg PAT-5A was given orally to Wistar rats for investigating the dose linearity in pharmacokinetics. In another study, a single intravenous bolus dose of PAT-5A was given to rats at 10 mg/kg dose following administration through the tail vein in order to obtain the absolute oral bioavailability and clearance parameters. Blood samples were drawn at predetermined intervals and concentration of PAT-5A in plasma was determined by a validated HPLC method. Plasma concentration versus time data was generated following oral and i.v. dosing and subjected to noncompartment pharmacokinetic analysis to obtain the values for the parameters. Both Cmax and AUC0-infinity appeared to increase proportionally to the administered oral doses. While the doses increased in the ratio of 1.0:3.3:10.0:33.3, the mean Cmax and AUC0-infinity increased in the ratio of 1.0:3.3:8.0:16.7 and 1:4.4:12.0:32.1, respectively. The systemic clearance and volume of distribution of PAT-5A in rats were 83.1 mL/h and 177.1 mL respectively after i.v. administration. Plasma concentrations declined monoexponentially following oral as well as intravenous administration and terminal half-life was about 1.4 h. There was no significant change in half-life with increase in oral doses. Absolute oral bioavailability of PAT-5A across the doses tested was in the range of 73-100% and this indicates that PAT-5A is neither a candidate for pre-systemic metabolism nor prone to absorption-related issues.
